An interim look at the phase 2 DESTINY-Lung01 study, presented at the World Conference on Lung Cancer, showed Enhertu could spur a benefit in 24.5% of heavily pretreated patients with HER2 ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

61.9% of patients with HER2-mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response. Breakthrough Therapy Designation recently granted in the US for ENHERTU in ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

After earning an FDA nod for breast cancer in December four months ahead of schedule, AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody-drug conjugate Enhertu is also showing some early prom ...

Friday, the drug scored an accelerated FDA approval in HER2-mutant non-small cell lung cancer. The nod came just a week after Enhertu nabbed a groundbreaking HER2-low nod in unresectable or ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most ...

“ENHERTU is the first therapy to demonstrate a strong and durable tumor response in patients with previously treated HER2 mutant advanced non-small cell lung cancer, validating HER2 as an actionable ...

AstraZeneca and Daiichi Sankyo Company, Limited’ s ENHERTU ® has been granted Breakthrough Therapy Designation in the US for the treatment of patients with metastatic non-small cell lung cancer ...

TOKYO & MUNICH, October 23, 2023--ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) as the first HER2-directed therapy for a subset of lung cancer patients. The EU ...

TOKYO & BASKING RIDGE, N.J., August 19, 2024--ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer ...